Cocrystal Pharma Announces the Publication by Collaborators of Positive Data Demonstrating Potent In Vitro Inhibition Against Coronavirus in Science Translational Medicine Journal
04 août 2020 08h05 HE
|
Cocrystal Pharma, Inc.
– Cocrystal has two exclusive licenses for the coronavirus protease inhibitors described in the publication – – Cocrystal is currently further conducting preclinical studies of these coronavirus...
COCRYSTAL PHARMA, INC. PRICES $2.2 MILLION REGISTERED DIRECT OFFERING
29 janv. 2020 09h45 HE
|
Cocrystal Pharma, Inc.
BOTHELL, WA, Jan. 29, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral...